Free Newsletter
SPOTLIGHT: GSK's Arixtra losing to Rivaroxaban
A research report concludes that GlaxoSmithKline's anti-clotting drug Arixtra is losing ground to Rivaroxaban, made and marketed by Bayer Schering/Johnson & Johnson. Released by Decision Resources, the report cites Arixtra's need for close monitoring and its potential for serious side effects such as hemorrhage. Article
More stories about GlaxoSmithKline
Comments
By Anonymous | Posted 4:29pm | May 22, 2008
That's amazing given that rivaroxaban hasn't been launched yet. Regarding hemorrrage and close monitoring, things that are not associated with Arixtra, maybe there is some confusion with warfarin...? What utter rubbish!
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
Click here to get the FiercePharma email newsletter for FREE!
Comments (2) | Post a comment